Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Grants Orphan Drug Designation to Toripalimab for Esophageal Cancer

November 16th 2021

The FDA granted an orphan drug designation to toripalimab for the treatment of patients with esophageal cancer.

Ku Reviews Exciting ESMO Data in Gastric/GEJ Cancer

November 15th 2021

Dr. Ku underscores key takeaways from the CheckMate649 and DESTINY-Gastric02 trials in gastric/GEJ cancer and highlights ongoing research that has the potential to further inform treatment selection and sequencing in the field

ESMO 2021 Updates in Metastatic Esophageal Squamous Cell Carcinoma

November 15th 2021

Experts in gastrointestinal cancers review recent updates and clinical implications from phase 3 trials presented at ESMO 2021 in metastatic esophageal squamous cell carcinoma (ESCC).

Pembrolizumab/Chemo Not Effective in Extrapulmonary Poorly Differentiated Neuroendocrine Carcinomas

November 15th 2021

The combination of pembrolizumab (Keytruda) and irinotecan- or paclitaxel-based chemotherapy was not found to be effective in pretreated, biomarker-unselected patients with extrapulmonary poorly differentiated neuroendocrine carcinomas.

Telotristat Ethyl Improves Symptoms and Patient Satisfaction in Carcinoid Syndrome

November 15th 2021

Patients with carcinoid syndrome reported improved symptoms following treatment with telotristat ethyl.

Surufatinib/Toripalimab Combo Elicits Encouraging Efficacy in Advanced Neuroendocrine Carcinoma

November 13th 2021

The combination of surufatinib and toripalimab demonstrated promising clinical activity with a manageable safety profile when used as second-line treatment for patients with advanced neuroendocrine carcinoma.

Surufatinib Induces Robust Responses in US Patients with Extrapancreatic and Pancreatic NETs

November 12th 2021

Surufatinib demonstrated strong antitumor activity along with a manageable safety profile in heavily treated US patients with progressive extrapancreatic neuroendocrine tumors or pancreatic NETs, according to interim phase 1 data.

Dr. Soares on the Standard of Care in Metastatic Pancreatic Cancer

November 11th 2021

Heloisa P. Soares, MD, PhD, discusses the standard of care in metastatic pancreatic cancer.

Immunotherapy Paves Path for New Standards of Care in Gastroesophageal Cancers

November 11th 2021

It is crucial to understand and interpret the results from the landmark clinical trials in the context of recent FDA approvals in gastroesophageal cancers.

FDA Grants Orphan Drug Designation to LYT-200 for Pancreatic Cancer

November 11th 2021

The FDA has granted an orphan drug designation to LYT-200, a fully human IgG4 monoclonal antibody targeting galectin-9, for use as a potential therapeutic option for patients with pancreatic cancer.

Lanreotide Demonstrates Confirmed Efficacy in Advanced Bronchopulmonary NETs

November 11th 2021

Lanreotide autogel/depot administered at 120 mg every 28 days may be an appropriate treatment for patients with advanced bronchopulmonary neuroendocrine tumors.

Saif Shares Insights on Single-Agent PARP Inhibitors and Combination Therapies for Pancreatic Cancer

November 10th 2021

Wasif M. Saif, MD, discusses the evolving role of PARP inhibitors and anticipated trends for research in pancreatic cancer.

Dr. Saif on the Rationale to Utilize PARP Inhibitors in BRCA+ Pancreatic Cancer

November 10th 2021

Wasif M. Saif, MD, MBBS, discusses the rationale to utilize PARP inhibitors in BRCA-mutated pancreatic cancer.

PEN-221 Demonstrates Clinical Benefit in Gastrointestinal NETs

November 10th 2021

The small molecule drug conjugate PEN-221 was generally well tolerated and elicited significant clinical benefit in patients with pretreated gastrointestinal neuroendocrine tumors.

Role of TACE and TARE in the Treatment of HCC

November 10th 2021

Andrea Casadei Gardini, MD, and Stephen L. Chan, MD, examine the use of TACE and TARE-Y90 for the treatment of HCC.

Updates to Adjuvant and Neoadjuvant Therapy in Early HCC

November 10th 2021

Stephen L. Chan, MD, reviews the case of a 72-year-old woman with mild alcoholic cirrhosis and provides insight on the potential role of adjuvant and neoadjuvant therapy for the treatment of HCC.

Finding the Optimal Therapeutic Sequence for Advanced Hepatocellular Carcinoma

November 10th 2021

Several breakthroughs in recent years have rapidly shifted the treatment landscape for advanced HCC.

DF1001 Gets Orphan Drug Designation From FDA for Esophageal Cancer

November 9th 2021

The FDA has granted an orphan drug designation to the HER2-targeted natural killer cell engager therapy, DF1001, as a potential therapeutic option for patients with esophageal cancer.

Dr. Mukherjee on Determining When to Initiate Immunotherapy in Gastroesophageal Cancer

November 9th 2021

Sarbajit Mukherjee, MD, MS, discusses considerations to inform when to initiate immunotherapy in gastroesophageal cancer.

Infigratinib Represents New Option for FGFR2+ Cholangiocarcinoma, as Efforts Shift to Target Other FGFR Alterations

November 9th 2021

Sameek Roychowdhury, MD, PhD, discusses the efficacy and safety data reported with infigratinib in FGFR2-positive cholangiocarcinoma, nuances to treatment with the agent, and ongoing research efforts to further improve outcomes in this population.